Skip to main content
RGEN logo

RGEN · Repligen Corp

Track RGEN — free
$166.83 -0.66 (-0.39%) At close · Aug 14
Market Cap
$9.42B
Shares
56.44M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$166.83 Open$167.49 Day$165.05–168.02 52W close$102.87–172.26 Avg vol 30d1.1M Short int6.1M · 10.9% float · 3.9d Short vol77% Last earningsJul 28, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 24, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Buy
      50 / 200-day cross Golden cross
      Price vs 200-day avg +19%
      above
      Price vs 50-day avg +17%
      above
      RSI (14) 70
      overbought
      MACD trend Positive
      52-week position 92%
      near high
      Momentum
      relative strength
      Very Strong
      1-month return +13%
      trailing
      6-month return +23%
      trailing
      YTD return +2%
      this year
      Relative strength +9%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Golden cross
      50d $142 › 200d $140 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +98 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.87% of float · ▲ +5.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      475 holders — mid 3-yr range
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +35%
      Y/Y
      EPS growth +287%
      Y/Y
      Free cash flow $93.9M
      Buyback $25.0M
      authorized
      Balance sheet $23.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 46%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 4.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 28, 2026
      Total Reported Revenue · FY 2026 $813M – $835M
      Organic Growth · FY 2026 10.5% – 13.5%
      Gross Margin · FY 2026 Non-GAAP 53.7% – 54.2%
      Income from Operations · FY 2026 Non-GAAP $128M – $134M
      Operating Margin · FY 2026 Non-GAAP 15.7% – 16%
      Other Income (Expense) · FY 2026 Non-GAAP $19M
      Adjusted EBITDA Margin · FY 2026 Non-GAAP 20.6% – 21%
      Earnings Per Share - Diluted · FY 2026 Non-GAAP $2.03 – $2.09
      Net Income · FY 2026 Non-GAAP $115.5M – $118.5M
      Prior guidance period ended · from the Earnings Call filed Jun 30, 2025
      Revenue · full year 2025 $715M – $735M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      1 · 0 · 5
      50 / 200-day cross
      Golden cross Bullish
      Price vs 200-day avg
      +19% Bullish
      Price vs 50-day avg
      +17% Bullish
      RSI (14)
      70 Bearish
      MACD trend
      Positive Bullish
      52-week position
      92% Bullish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) Golden cross
      50d $142 › 200d $140 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +98 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.87% of float · ▲ +5.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      475 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $103 Now $167 · 92% Range high $172
      vs 200-day avg +19% vs 50-day avg +17% 50-day above 200-day golden cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Medical Instruments & Supplies — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RGEN
      Repligen Corp
      this stock
      $9.42B +1.8% +35.1% 10.9%
      ISRG
      Intuitive Surgical Inc
      $139.37B -30.3% +20.5% 45.3 1.9%
      BDX
      Becton Dickinson & Co
      $49.96B +8.2% 3.7%
      MDLN
      Medline Inc.
      $46.99B -14.9% +11.5% 2.6%
      ALC
      Alcon Inc
      $35.89B -5.8% +10.5% 2.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      475
      % held
      113.0%
      Net QoQ
      -2.2M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      578
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.1M
      Days to cover
      3.9d
      Change
      +320.8K sh
      View
      Short Volume
      Short vol %
      77%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      458
      Value
      $66.4K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      45.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Lisa McClain
      Amount
      $1.0K–$15.0K
      Traded
      Oct 31, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $141.2M
      Net income (FY)
      $48.9M
      EPS diluted
      $0.86
      View
      Buybacks
      Authorized
      $25.0M
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Jul 29, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $79.5K
      Shares
      530
      Filed
      Jul 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 28, 2026
      View
      Investor Relations
      Latest news
      Repligen Reports Second Quarter 2…
      Published
      Jul 28, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      RGEN +1.8% +13.3% +23.2% +18.3% +1.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +1.4% +8.9% +9.4% +14.4% -12.0%

      Capital returns

      Buyback program · as of Dec 31, 2023
      Authorized
      $25.00M
      Spent (derived)
      Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 730272 CUSIP 759916109 13F (30d) 461 filings 436 filers Visit website Investor relations